G1 Therapeutics rises on positive drug data from breast cancer trial

G1 Therapeutics

05/06/2023 14:24

** Shares of drugmaker G1 Therapeutics Inc  GTHX.O  up 10.7%
at $2.90 premarket
    ** Company on Sunday reported positive data from mid-stage
trial of its drug trilaciclib to treat patients with early-stage
triple-negative breast cancer, which has limited treatment
options
    ** Trial enrolled 24 patients to test immune-based mechanism
of action of a single dose of trilaciclib
    ** Treatment enhanced the number and function of a type of
white blood cells that can kill infected or cancer cells -
company
    ** Trilaciclib increased generation of certain memory T
cells in the tumor microenvironment 
    ** Memory T cells remain long-term in the body after an
infection has been eliminated and are responsible for providing
long-term immune surveillance and efficacy
    ** As of last close, stock up 45.96% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))